Full Press Release Details
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS Regeneron’s first marketing application is accepted for review by the FDA.
REGN
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS Regeneron’s first marketing application is accepted for review by the FDA
Key Takeaway: Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS Regeneron’s first marketing application is accepted for review by the FDA
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
2.7%
average across 15 past catalysts
Lead asset
REGN7508
Phase 3 · Venous Thromboembolism